June 26, 2013
Life Technologies Corporation
(NASDAQ: LIFE) announces that its
Applied Biosystems® 7500 Fast Dx Real-Time PCR
instrument is suitable for use with the
CDC Novel Coronavirus 2012 Real-time RT-PCR
Assay, which has received Emergency Use Authorization for detection in patient specimens of the novel Middle East Respiratory Syndrome Coronavirus (MERS-CoV). To date the virus has been found in
United Arab Emirates
. Globally, since
World Health Organization (WHO)
has been informed of a total of 64 laboratory-confirmed cases of the infection with MERS-CoV, including 38 deaths.
Additionally, the CDC Novel Coronavirus 2012 Assay can be performed using Life's SuperScript III One-Step qRT-PCR reagent kit. The Respiratory Syndrome Coronavirus (MERS-CoV) Assay is intended to quickly monitor the spread of the pathogen and thwart a potential pandemic. To support this global need, Life Technologies is increasing production of its reagents and shipping them to labs around the world. This test has been authorized only for the diagnosis of Respiratory Syndrome Coronavirus (MERS-CoV) and not for the diagnosis of any other viruses or pathogens.
"We are working continually with our partners to improve capabilities, particularly tests that work more quickly and simply on more people," said
, president and chief operating officer at Life Technologies. "Our technology aids public health labs around the globe to identify threats and develop rapid detection kits."
The test has been authorized by FDA under an Emergency Use Authorization for use by qualified laboratories. The CDC Novel Coronavirus 2012 Assay has not been FDA cleared or approved.